Exane Derivatives’s AmTrust Financial Services, Inc. AFSI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-4
| Closed | -$58 | – | 763 |
|
|
2018
Q3 | $58 | Hold |
4
| – | – | ﹤0.01% | 640 |
|
|
2018
Q2 | $58 | Hold |
4
| – | – | ﹤0.01% | 636 |
|
|
2018
Q1 | $50 | Hold |
4
| – | – | ﹤0.01% | 574 |
|
|
2017
Q4 | $40 | Buy |
+4
| New | +$45 | ﹤0.01% | 574 |
|
|
2017
Q3 | – | Sell |
-4
| Closed | -$61 | – | 667 |
|
|
2017
Q2 | $61 | Hold |
4
| – | – | ﹤0.01% | 581 |
|
|
2017
Q1 | $74 | Hold |
4
| – | – | ﹤0.01% | 505 |
|
|
2016
Q4 | $110 | Hold |
4
| – | – | ﹤0.01% | 537 |
|
|
2016
Q3 | $107 | Hold |
4
| – | – | ﹤0.01% | 532 |
|
|
2016
Q2 | $98 | Hold |
4
| – | – | ﹤0.01% | 470 |
|
|
2016
Q1 | $104 | Buy |
+4
| New | +$106 | ﹤0.01% | 531 |
|
|
2015
Q4 | – | Sell |
-4
| Closed | -$126 | – | 579 |
|
|
2015
Q3 | $126 | Hold |
4
| – | – | ﹤0.01% | 483 |
|
|
2015
Q2 | $131 | Hold |
4
| – | – | ﹤0.01% | 484 |
|
|
2015
Q1 | $114 | Buy |
+4
| New | +$108 | ﹤0.01% | 489 |
|
Exane Derivatives's AFSI Position: Q4 2018 in Review
Exane Derivatives sold out of AmTrust Financial Services, Inc. (AFSI) in Q4 2018, closing a stake of 4 shares — an estimated $58 sold.
Exane Derivatives first reported a position in AFSI in Q1 2015 and held it in 13 quarters. The position peaked at $131 in Q2 2015. 1 fund tracked by Wall St. Rank holds AFSI as of Q4 2018.
- Exane Derivatives reported no remaining AmTrust Financial Services, Inc. position as of Q4 2018 after selling out during the quarter.
- Exane Derivatives sold 4 AmTrust Financial Services, Inc. shares in Q4 2018, an estimated $58.
- Exane Derivatives first reported a position in AmTrust Financial Services, Inc. in Q1 2015 and held it in 13 quarters.
- Exane Derivatives's AmTrust Financial Services, Inc. position peaked at $131 in Q2 2015.
- 1 fund tracked by Wall St. Rank held AmTrust Financial Services, Inc. as of Q4 2018.
Based on Exane Derivatives's 13F filing for Q4 2018, filed 31 Jan 2019.